Infection ControlNCT05597072
Bacterial Air Contamination
A study testing Intervention in people with Infection Control, run by Camilla Wistrand at 1 site in Sweden.
Trial summary
Aim is to compare the effect of number of persons and time-dependant bacterial air contamination on sterile goods, using different preparation conditions and protective sterile covers. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Infection Control
- What is being tested?
- Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteSweden
- Study dates
- 17 May 2022to 31 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Consecutive patients (n=70) undergoing cardiac surgery at the Department of Cardiothoracic and Vascular Surgery at Örebro University Hospital (ÖUH), Region Örebro County will be identified. Inclusion criteria: patients undergoing cardiac surgery by median sternotomy; coronary artery bypass grafting (CABG), aneurysm, valve replacement or combination surgery.
Who cannot join
- Patients where partial thoracotomy or endovascular procedures are performed. Patients with infection and procedures as infective endocarditis. No research nurse available.
Trial locations and contacts
1 site in 1 country.
Ann-Sofie Sundqvist, PhD contact
Sweden1 site, 1 recruiting
- Recruiting
University Hospital
Örebro, 70185
Camilla Wistrand, PhD, +46707686938, camilla.wistrand@regionorebrolan.se
Ann-Sofie Sundqvist, ann-sofie.sundqvist@regionorebrolan.se
About this study
Official title: Infection Control - Time-dependant Bacterial Air Contamination in the Operating Room
Aim is to compare the effect of number of persons and time-dependant bacterial air contamination on sterile goods, using different preparation conditions and protective sterile covers.
Research questions Is there a difference in bacterial air contamination during preparation of the sterile surgical goods with 2 persons (intervention) compared with 4-5 persons (control) in the OR? Is there a time-dependent difference in bacterial air contamination pending surgery for 1 hour (control) compared to approximately 12 hours (intervention) when the sterile goods are protected with sterile covers? Is there a time-dependent difference in bacterial air contamination pending surgery if sterile goods are protected or not, by sterile covers? Is there any differences in surgical site infections between the groups? What type of bacteria contain the air contamination? Is there antibiotic resistant bacterial air contamination?
Read the detailed description
Intervention - In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention). The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons). Thereafter, the sterile goods will be protected with sterile covers (time pending surgery will be approximately one hour). For allocation, a computer-generated randomization list will be produced and an independent secretary will be arranging the printed notes showing the group assignment in ordered, sealed, non-transparent envelopes.
To measure the time pending surgery tables will be arrange with blood agar plates to measure the bacterial air contamination. There will be two tables, one protected with sterile covers and one left without protective covers (in both intervention- and control group).
Outcomes and materials - Primary outcome is bacterial growth isolated by aerobe and anaerobe blood agar plates (haematin agar medium 4.3% w/v [Colombia Blood Agar Base] supplemented with 6% w/v chocolatized defibrinated horse blood) and FAA plates (LAB 90 Fastidious Anaerobe Agar 4.6% w/v supplemented with 5% w/v defibrinated horse blood). Secondary outcome is surgical site infections with comparison of bacteria type.
Data collection - A total of 1260 blood agar plates will be used to capture bacterial air contamination. To capture differences in bacterial air contamination during different preparation conditions of the sterile goods, six agar plates (three haematin and three FAA) will be set on a table as the preparation begins. When preparation is complete the agar plates will be collected, by closing the lid of the agar plates. To measure the time-dependant bacterial air contamination pending surgery new agar plates (three haematin and three FAA) which will be set on tables for both intervention- and control group and covered with sterile drapes. To measure the effectiveness of sterile coverage from bacterial air contamination agar plates will be left uncovered pending surgery in both intervention- and control group. When preparing the patient for surgery the covers will be removed and all the plates will be collected by closing the lids.
Microbiology - The plates will be analysed at the Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, according to a specific study protocol. The haematin plates will be incubated at 36°C under aerobic conditions while the FAA plates will be incubated under anaerobic conditions (10% H2, 10% CO2, 80% N2) at 37°C. After 24 and 48 h of aerobic incubation and five days of anaerobic incubation, bacterial growth will be determined quantitatively by counting colony-forming units per plate. The isolates will be identified by routine diagnostic procedures and determined to species level via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Microflex LT and Biotyper 3.1, Bruker Daltonik, Bremen, Germany).
Standard antibiotic susceptibility testing for staphylococci will be performed by the disc diffusion test for cefoxitin (30 mg), fusidic acid (10 mg), erythromycin (15 mg), clindamycin (2 mg), trimethoprim/sulfamethoxazole (25 mg), gentamicin (10 mg), norfloxacin (10 mg), ciprofloxacin (5 mg), and rifampin (5 mg) (all antibiotic discs from Oxoid, Basingstoke, UK) with a 0.5 McFarland bacterial suspension in 0.85% NaCl on Mueller-Hinton II agar 3.8% w/v plates (BD Diagnostic Systems, Sparks, MD, USA). After 16-20 h of incubation at 35°C, the zone diameters will be measured and each isolate will be evaluated according to European Committee on Antimicrobial Susceptibility Testing breakpoints (http://www.eucast.org). Isolates resistant to at least three of the antibiotic groups tested will be considered multidrug resistant.
The susceptibility of Cutibacterium acnes to benzylpenicillin and clindamycin will be investigated using a gradient test. Minimum inhibitory concentrations will be determined by Etest (bioMe´rieux, Marcy l'Etoile, France) on FAA plates (LAB M) with 0.5 McFarland suspensions of bacteria in NaCl and incubation at 36°C in an anaerobic atmosphere for 24 h. For metronidazole, a disc (Oxoid) will be used. Bacterial genomic sequencing may be analysed in order to understand if the bacteria derives from the persons within the OR or the hospital environment.
All data regarding postoperative infections will be retrieved from a local register Carath, Department of Cardiothoracic and Vascular surgery. A case report form (CRF) will be used to collect data regarding patient characteristics, OR settings (e.g. temperature, air humidity, number of persons, number of door openings) and surgical data (e.g. type of surgery, time for surgery).
- Conditions
- Infection Control
- Being tested
- Intervention, Control
- Keywords
- Infection control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterventionBehavioural
Less people within the OR but longer waiting time.
ControlBehavioural
More people in the OR but shorter waiting time
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention). Receives: Behavioral: Intervention |
| Control | Active comparator | The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons). Receives: Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Colony forming units
Bacterial growth
Measured: from one to 15 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2022
- Study start17 May 2022
- Primary completion30 Nov 2023 (estimated)
- Study completion31 May 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Infection ControlStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Camilla Wistrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Camilla Wistrand, Örebro University, Sweden
- Investigators
- Camilla Wistrand, PhD, Principal investigator, Örebro University, Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05597072
- Sponsor's protocol ID
- BAirCon 2022
- Status last verified
- Oct 2022
- First submitted
- 24 Oct 2022
- Last updated
- 27 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Wistrand C, Soderquist B, Sundqvist AS. The effect of five versus two personnel on bacterial air contamination during preparation of sterile surgical goods in the operating room: a randomised controlled trial. Antimicrob Resist Infect Control. 2025 Jun 15;14(1):68. doi: 10.1186/s13756-025-01589-4.
PubMed 40518530Wistrand C, Soderquist B, Friberg O, Sundqvist AS. Bacterial air contamination and the protective effect of coverage for sterile surgical goods: A randomized controlled trial. Am J Infect Control. 2025 Apr;53(4):467-472. doi: 10.1016/j.ajic.2024.12.012. Epub 2024 Dec 16.
PubMed 39694445
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Infection Control - Time-dependant Bacterial Air Contamination in the Operating Room
- ClinicalTrials.gov ID
- NCT05597072
- Acronym / sponsor ID
- BAirCon 2022
- Conditions
- Infection Control
- Keywords
- Infection control
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Camilla WistrandUniversity, hospital or other
- Study start
- 17 May 2022 (actual)
- Primary completion
- 30 Nov 2023 (estimated)
- Study completion
- 31 May 2024 (estimated)
- First posted
- 27 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim is to compare the effect of number of persons and time-dependant bacterial air contamination on sterile goods, using different preparation conditions and protective sterile covers.
Research questions Is there a difference in bacterial air contamination during preparation of the sterile surgical goods with 2 persons (intervention) compared with 4-5 persons (control) in the OR? Is there a time-dependent difference in bacterial air contamination pending surgery for 1 hour (control) compared to approximately 12 hours (intervention) when the sterile goods are protected with sterile covers? Is there a time-dependent difference in bacterial air contamination pending surgery if sterile goods are protected or not, by sterile covers? Is there any differences in surgical site infections between the groups? What type of bacteria contain the air contamination? Is there antibiotic resistant bacterial air contamination?
Detailed description
Intervention - In the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention). The control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons). Thereafter, the sterile goods will be protected with sterile covers (time pending surgery will be approximately one hour). For allocation, a computer-generated randomization list will be produced and an independent secretary will be arranging the printed notes showing the group assignment in ordered, sealed, non-transparent envelopes.
To measure the time pending surgery tables will be arrange with blood agar plates to measure the bacterial air contamination. There will be two tables, one protected with sterile covers and one left without protective covers (in both intervention- and control group).
Outcomes and materials - Primary outcome is bacterial growth isolated by aerobe and anaerobe blood agar plates (haematin agar medium 4.3% w/v [Colombia Blood Agar Base] supplemented with 6% w/v chocolatized defibrinated horse blood) and FAA plates (LAB 90 Fastidious Anaerobe Agar 4.6% w/v supplemented with 5% w/v defibrinated horse blood). Secondary outcome is surgical site infections with comparison of bacteria type.
Data collection - A total of 1260 blood agar plates will be used to capture bacterial air contamination. To capture differences in bacterial air contamination during different preparation conditions of the sterile goods, six agar plates (three haematin and three FAA) will be set on a table as the preparation begins. When preparation is complete the agar plates will be collected, by closing the lid of the agar plates. To measure the time-dependant bacterial air contamination pending surgery new agar plates (three haematin and three FAA) which will be set on tables for both intervention- and control group and covered with sterile drapes. To measure the effectiveness of sterile coverage from bacterial air contamination agar plates will be left uncovered pending surgery in both intervention- and control group. When preparing the patient for surgery the covers will be removed and all the plates will be collected by closing the lids.
Microbiology - The plates will be analysed at the Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, according to a specific study protocol. The haematin plates will be incubated at 36°C under aerobic conditions while the FAA plates will be incubated under anaerobic conditions (10% H2, 10% CO2, 80% N2) at 37°C. After 24 and 48 h of aerobic incubation and five days of anaerobic incubation, bacterial growth will be determined quantitatively by counting colony-forming units per plate. The isolates will be identified by routine diagnostic procedures and determined to species level via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Microflex LT and Biotyper 3.1, Bruker Daltonik, Bremen, Germany).
Standard antibiotic susceptibility testing for staphylococci will be performed by the disc diffusion test for cefoxitin (30 mg), fusidic acid (10 mg), erythromycin (15 mg), clindamycin (2 mg), trimethoprim/sulfamethoxazole (25 mg), gentamicin (10 mg), norfloxacin (10 mg), ciprofloxacin (5 mg), and rifampin (5 mg) (all antibiotic discs from Oxoid, Basingstoke, UK) with a 0.5 McFarland bacterial suspension in 0.85% NaCl on Mueller-Hinton II agar 3.8% w/v plates (BD Diagnostic Systems, Sparks, MD, USA). After 16-20 h of incubation at 35°C, the zone diameters will be measured and each isolate will be evaluated according to European Committee on Antimicrobial Susceptibility Testing breakpoints (http://www.eucast.org). Isolates resistant to at least three of the antibiotic groups tested will be considered multidrug resistant.
The susceptibility of Cutibacterium acnes to benzylpenicillin and clindamycin will be investigated using a gradient test. Minimum inhibitory concentrations will be determined by Etest (bioMe´rieux, Marcy l'Etoile, France) on FAA plates (LAB M) with 0.5 McFarland suspensions of bacteria in NaCl and incubation at 36°C in an anaerobic atmosphere for 24 h. For metronidazole, a disc (Oxoid) will be used. Bacterial genomic sequencing may be analysed in order to understand if the bacteria derives from the persons within the OR or the hospital environment.
All data regarding postoperative infections will be retrieved from a local register Carath, Department of Cardiothoracic and Vascular surgery. A case report form (CRF) will be used to collect data regarding patient characteristics, OR settings (e.g. temperature, air humidity, number of persons, number of door openings) and surgical data (e.g. type of surgery, time for surgery).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: InterventionIn the evening before an elective surgery the sterile surgical goods will be prepared under calm circumstances with only 2 persons in the OR (intervention). Thereafter, the sterile goods will be protected with sterile covers and time pending surgery will be approximately 12 hours (intervention). |
| Control | Active comparator | Behavioral: ControlThe control is to prepare the sterile goods in the morning with more people in the OR (approximately 4-5 persons). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Consecutive patients (n=70) undergoing cardiac surgery at the Department of Cardiothoracic and Vascular Surgery at Örebro University Hospital (ÖUH), Region Örebro County will be identified. Inclusion criteria: patients undergoing cardiac surgery by median sternotomy; coronary artery bypass grafting (CABG), aneurysm, valve replacement or combination surgery.
Key exclusion criteria (1 listed)
- Patients where partial thoracotomy or endovascular procedures are performed. Patients with infection and procedures as infective endocarditis. No research nurse available.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterventionLess people within the OR but longer waiting time. | Behavioural | Intervention |
| ControlMore people in the OR but shorter waiting time | Behavioural | Control |
Primary outcome
Colony forming units
Time frame: from one to 15 hours
Bacterial growth
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2022.
- Derived from this study: PubMed 40518530Wistrand C, Soderquist B, Sundqvist AS. The effect of five versus two personnel on bacterial air contamination during preparation of sterile surgical goods in the operating room: a randomised controlled trial. Antimicrob Resist Infect Control. 2025 Jun 15;14(1):68. doi: 10.1186/s13756-025-01589-4.
- Derived from this study: PubMed 39694445Wistrand C, Soderquist B, Friberg O, Sundqvist AS. Bacterial air contamination and the protective effect of coverage for sterile surgical goods: A randomized controlled trial. Am J Infect Control. 2025 Apr;53(4):467-472. doi: 10.1016/j.ajic.2024.12.012. Epub 2024 Dec 16.
- Individual participant dataSharing planned: No
Related trials for Infection Control
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingPhase 1
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
EBV
RecruitingPhase 3
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL
Sepsis
Recruiting
A Multicenter Randomized Trial of CT-Based AI Decision Support for Early Pneumonia Care
Pneumonia; Pulmonary Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ann-Sofie Sundqvist, PhD contact
Camilla Wistrand, PhD principal investigator
Örebro University, Sweden
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention in people with Infection Control, run by Camilla Wistrand at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Camilla Wistrand, PhD (+46707686938, camilla.wistrand@regionorebrolan.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Colony forming units (time frame: from one to 15 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05597072, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2022.